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Successful treatment of melanoma patients with check-
point inhibitors (CPI) has reinforced the importance of
T cells in anti-tumor efficacy. Despite significant pro-
gress, CPI therapy is effective in only 40-50% of treated
subjects, with substantial toxicity. As a result, it is
imperative to understand the profile of T cell responses
to tumor antigens, to determine if patterns of responsive-
ness can be identified for those subjects who respond to
immunotherapy. ATLASTM is a T cell antigen discovery
platform in which putative antigens are expressed as indi-
vidual clones that can be processed by any subject’s anti-
gen presenting cells and presented as peptide epitopes in
the context of their own MHC class I or II molecules.
If autologous CD4+ or CD8+ T cells are added that are
specific for a given clone in a given well, a readout of
activation can be measured. We hypothesized that the
ATLAS™ technology could be applied to characterize
and profile the T cell responses to tumor-associated anti-
gens (TAA) of diverse human subjects undergoing CPI
therapy. As a proof of concept, an expression library con-
taining 23 full-length melanoma TAA was constructed
and used to interrogate memory CD4+ and CD8+ T cell
responses from of a cohort of melanoma patients who
have undergone treatment with pembrolizumab. All 23
TAA were cloned and sequence verified; 96% and 91%
were successfully expressed in the CD4-specific and
CD8-specific library, respectively. Peripheral blood
mononuclear cells (PBMC) were collected from ten
patients who had undergone immunotherapy with pem-
brolizumab; CD4+ and CD8+ T cells were sorted and
non-specifically expanded, and monocytes differentiated
into dendritic cells (MDDC) in vitro. PBMC yields were
comparable to historical assay data with the exception of
lower viability of MDDC. Memory T cell responses to
TAA were detectable and this study suggests that T cell
responses to TAA can be measured in multiple, HLA-
diverse subjects during CPI therapy, without the need to
derive cell lines or use predictive algorithms. Work is
currently underway to increase both the number of anti-
gens and participants evaluated. Analyses will include the
frequency and breadth of responses and the relationship
between CD4+ and CD8+ T cell responses in subjects
who benefit from CPI therapy compared with those who
do not. This work has implications for both patient stra-
tification and identification of novel immunotherapies.
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